Market Place
Sourcing Support
Azura Ophthalmics: First Patient In Phase 3 MGD Trial For AZR-MD-001
04 Jun 2024 //
BUSINESSWIRE
Azura Ophthalmics to Present Data of AZR-MD-001 for Ocular Surface Diseases
28 Mar 2024 //
BUSINESSWIRE
Azura Announces Positive Results from Phase 2 Clinical Trial of AZR-MD-001
18 Dec 2023 //
BUSINESSWIRE
Azura Ophthalmics to Present New Data on AZR-MD-001 Gland Dysfunction
20 Apr 2023 //
BUSINESSWIRE
Azura Ophthalmics Announces Participation at the 2023 SVB Conference
17 Jan 2023 //
BUSINESSWIRE
Azura Presents Positive Results from Phase 2b Clinical Trial of AZR-MD-001
09 Dec 2022 //
BUSINESSWIRE
Azura Ophthalmics Announces Participation at Upcoming Investor Conferences
21 Nov 2022 //
BUSINESSWIRE
Azura Announces Positive Results from Phase 2b Clinical Trial of AZR-MD-001
17 Nov 2022 //
BUSINESSWIRE
Azura Expands Intellectual Property Portfolio to 12 U.S. & European Patents
19 Oct 2022 //
BUSINESSWIRE
Azura Ophthalmics Provides Update on AZR-MD-001 Phase 2 Clinical Program
28 Sep 2022 //
BUSINESSWIRE
Azura Ophthalmics Announces Formation of Scientific Advisory Board (SAB)
21 Sep 2022 //
BUSINESSWIRE
Azura Ophthalmics Secures Grant to Evaluate AZR-MD-001
07 Sep 2022 //
BUSINESSWIRE
Azura Ophthalmics Appoints Biopharma Industry Veteran Steven Altschuler
07 Sep 2021 //
BUSINESSWIRE
Azura Ophthalmics Announces Positive Topline Results From Phase 2 Program
03 Mar 2021 //
BUSINESSWIRE
Azura Ophthalmics Announces Positive Topline Results From Phase 2
03 Mar 2021 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.